Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

27

Revenue 2017

Gilenya

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Gilenya was produced by Novartis.

Cortellis Drugs to Watch in 2020 report

Cortellis Drugs to Watch in 2020 report

To succeed, it will have to differentiate from its direct competitors, particularly the first-in-class S1P1 agonist Gilenya, by leveraging potential cardiovascular safety advantages.

J&J aims for US approval of MS drug ponesimod

J&J aims for US approval of MS drug ponesimod If approved, ponesimod will compete directly with Novartis’ S1P receptor modulator franchise, which includes Gilenya (fingolimod) and follow-up Mayzent (siponimod), which is approved for secondary progressive forms of MS only ... There is also the

J&J’s ponesimiod tops Aubagio in head-to-head MS trial

J&J’s ponesimiod tops Aubagio in head-to-head MS trial S1P receptor modulator franchise based on Gilenya(fingolimod) and recently-launched follow-up  Mayzent(siponimod), which for now is approved for secondary progressive forms of MS only. ... There is also a looming threat of generic competition to Gilenya

Merck takes evobrutinib for MS into phase 3, on mixed data

Merck takes evobrutinib for MS into phase 3, on mixed data Novartis’ Gilenya (fingolimod) and Sanofi’s Aubagio (teriflunomide).

CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

CHMP backs Bayer’s tumour-agnostic drug Vitrakvi Finally, the panel recommended that Novartis’ multiple sclerosis drug Gilenya (fingolimod) should not be used in pregnant women and in women able to have children who are not using effective contraception

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

The search for treatments for Parkinson’s disease
The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...
Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.
Ditch the Label – it’s just me....
The impact of COVID-19 on clinical trials
As all industry sectors work to assess both the impact and the optimal path forward, the effects are expected to be diverse and long-lasting...

Infographics